Jilin Aodong Pharmaceutical Group (000623) Stock Overview
Jilin Aodong Pharmaceutical Group Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
000623 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Jilin Aodong Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.65 |
| 52 Week High | CN¥22.08 |
| 52 Week Low | CN¥14.85 |
| Beta | 0.62 |
| 1 Month Change | -1.43% |
| 3 Month Change | -3.02% |
| 1 Year Change | 13.44% |
| 3 Year Change | 24.33% |
| 5 Year Change | 17.96% |
| Change since IPO | 509.78% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Jilin Aodong Pharmaceutical Group (SZSE:000623) Use Debt?
Mar 14
Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) Could Be Riskier Than It Looks
Jan 17We Think That There Are More Issues For Jilin Aodong Pharmaceutical Group (SZSE:000623) Than Just Sluggish Earnings
Nov 06Market Might Still Lack Some Conviction On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) Even After 36% Share Price Boost
Oct 01A Look At The Intrinsic Value Of Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Aug 22Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60
Jul 05Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Jun 03There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings
Apr 23Shareholder Returns
| 000623 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.05% | -0.4% | -2.9% |
| 1Y | 13.4% | 11.5% | 25.0% |
Return vs Industry: 000623 exceeded the CN Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: 000623 underperformed the CN Market which returned 25% over the past year.
Price Volatility
| 000623 volatility | |
|---|---|
| 000623 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 000623 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000623's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 5,454 | Shuqin Guo | www.jlaod.com |
Jilin Aodong Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China. The company provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine.
Jilin Aodong Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 000623 fundamental statistics | |
|---|---|
| Market cap | CN¥21.86b |
| Earnings (TTM) | CN¥2.57b |
| Revenue (TTM) | CN¥2.34b |
Is 000623 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000623 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.34b |
| Cost of Revenue | CN¥1.31b |
| Gross Profit | CN¥1.03b |
| Other Expenses | -CN¥1.54b |
| Earnings | CN¥2.57b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 18, 2026
| Earnings per share (EPS) | 2.19 |
| Gross Margin | 44.09% |
| Net Profit Margin | 109.67% |
| Debt/Equity Ratio | 7.2% |
How did 000623 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 17:29 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jilin Aodong Pharmaceutical Group Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weina Jiang | Everbright Securities Co. Ltd. |
| null Research Department | Guotai Junan International Holdings Limited |
| Ziqin Shao | Ping An Securities Co. Ltd. |